Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Nivolumab maintenance in advanced squamous NSCLC
NCT03542461Phase 3Unknown
- Sponsor
- Gruppo Oncologico Italiano di Ricerca Clinica
- Start
- Sep 2017
- Primary completion
- Jan 2023
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of nivolumab in squamous cell carcinoma of the lung (SCCL) (2 arms), sponsored by Gruppo Oncologico Italiano di Ricerca Clinica. Primary endpoint: Overall Survival at 14 months. Status: unknown.
02
Drugs
03
Conditions
squamous cell carcinoma of the lung (SCCL)
Beyond the preview
Go deeper on NCT03542461.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03542461.